The FDA added Kybella warning information after reviewing adverse-event reports involving deoxycholic acid injections outside the approved under-chin area. The agency identified 129 non-submental cases and 117 unresolved nodules or masses, clarifying the safety boundary between FDA-approved submental treatment and broader injection-lipolysis claims.
The FDA’s September 23–24, 2026 workshop on the GLP-1 generic drug pathway marks a major regulatory shift from broad policy statements toward detailed scientific expectations. FDA and academic experts addressed peptide sameness, impurity profiling, immunogenicity, oral delivery, injector compatibility, human factors, and bioequivalence. The event does not mean generic semaglutide or tirzepatide is approved, but it shows how regulators are preparing for a larger wave of complex peptide competition.
FDA’s September 21, 2026 revision to Import Alert 66-80 adds specified orforglipron API and intermediate entries to the Green List framework, updates product coding and details manufacturer documentation FDA may evaluate. The 21% figure among 48 assessed sites remains important context from the ongoing GLP-1 API compliance effort.
A peer-reviewed phase 2 trial published September 17, 2026, found that once-weekly BGM0504 produced dose-dependent weight loss of up to 18.33% at 24 weeks in Chinese adults with overweight or obesity without diabetes. The dual GLP-1/GIP agonist produced a substantial placebo-controlled signal, but the 120-person study, short follow-up, specific population, and frequent gastrointestinal adverse events leave important questions for larger trials.
The FDA’s February 4, 2026 alert on unapproved GLP-1 drugs brings several risks into one regulatory warning: more than 1,720 reported adverse events involving compounded semaglutide and tirzepatide, fraudulent pharmacy labels, dosing errors, questionable salt forms, shipping-temperature failures, and illegal retatrutide marketing. Here is what the alert means and how it changes the quality conversation around unapproved weight-loss injections.
The FDA added three more products to its continuing yellow oleander safety alert on September 17, 2026. Laboratory testing found toxic yellow oleander in two Niwali products and Easy Forte Natural Fiber, reinforcing concerns that botanical weight-loss products may be substituted, mislabeled, or contaminated. The update is materially different from the agency’s August warning because it expands the investigation beyond products explicitly labeled as tejocote root and shows that the problem is continuing across multiple product formats and selling channels.
A 60-week randomized controlled trial provides unusually detailed evidence about how semaglutide changes eating behavior over time. Participants receiving semaglutide 2.4 mg consumed fewer calories at weeks 20, 40, and 60, while some subjective appetite and food-reward effects became less distinct after the first 20 weeks. The findings help explain why reduced energy intake can persist even when people no longer report the same intensity of appetite suppression.
The FDA’s January 13, 2026 decision to request removal of suicidal ideation and behavior warnings from certain GLP-1 drug labels closes a major safety question that began with postmarketing reports in 2023. The agency said its review of clinical trials, observational studies, pooled analyses, and case reports found no increased risk of suicidal thoughts or behavior associated with GLP-1 receptor agonists. This evidence-first analysis explains what changed, what the FDA actually concluded, why the warning existed, and what the decision does—and does not—mean for semaglutide, liraglutide, tirzepatide, and the next generation of obesity medicines.
A first-in-human UBT251 phase 1a/1b trial published September 8, 2026, provides the clearest peer-reviewed human data yet on Novo Nordisk’s licensed GLP-1/GIP/glucagon triple agonist. Participants with overweight or obesity receiving once-weekly UBT251 lost an average of 8.96 to 13.48 kilograms over 12 weeks, while placebo participants gained 1.57 kilograms. The study also reported reductions in glucose and lipid measures, generally acceptable tolerability, and approximately linear pharmacokinetics. The results are significant because they move UBT251 from a largely China-based development story into published first-in-human evidence, while also showing why the drug cannot yet be compared directly with approved obesity medicines or late-stage retatrutide data.
A new Nature study has placed semaglutide in the longevity conversation. Researchers found that treatment begun in 20-month-old female mice extended median lifespan from 742 to 834 days while improving physical function, glucose control, exploratory behavior, spatial memory, stem-cell activity, inflammation, and several molecular markers associated with aging. The findings are striking, but they remain animal data—not evidence that people should take semaglutide for life extension.
